Overview

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

Status:
Active, not recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

Summary

This is a randomized, multi-center, double-blind, Phase III study of radium-223 plus enzalutamide or darolutamide compared to enzalutamide or darolutamide treatment plus placebo.

Phase:

Phase 3

Details

Lead Sponsor:

MANA RBM

Collaborators:

Barbara Ann Karmanos Cancer Institute
Bayer
Carolina Urologic Research Center
Tulane University